Using a proprietary CALM bio-sensing platform, GTcardio continuously monitors key hemodynamics indicators including blood pressure, heart rate and cardiac output to provide a complete view of the dynamics of blood circulation.
GTcardio's technology is based on single-site photoplethysmography (PPG) readings which involves measuring the volumetric pulsations of blood in tissue; these pulsations are associated with the arterial pressure pulse. PPG readings can be integrated into wearable devices.
This technology can be used in a variety of clinical settings, including intensive care units, emergency departments, outpatient clinics or general wellness. – We are researching its applicability across multiple fields including longevity, neurodegenerative diseases (Alzheimer), chronic diseases, and metabolic disorders (diabetes).
For more information contact info@gtcardio.com
About GTcardio Inc.
GTcardio is a biotechnology company that specializes in the development of non-invasive continuous cardiovascular monitoring. The company's flagship product is a patented platform that allows for real-time monitoring of hemodynamics indicators including blood pressure and cardiac output. This technology is designed to improve patient outcomes and reduce healthcare costs by providing accurate and timely information to clinicians. The company has received several awards and recognitions for its innovative technology, and holds several patents in the area of continuous hemodynamics.
GTcardio is headquartered in Silicon Valley, CA and has offices in Israel, China, Japan, and India.
GTcardio Inc. 1024 Marilyn drive, Mountain View, California 94040, USA